Vasculitis and Giant Cell Arteritis News

Since the beginning of the COVID-19 pandemic, there has been a “significant decrease” in the risk for post-acute sequelae of COVID-19 among patients with rheumatic diseases, according to data published in The Journal of Rheumatology.

Patients with prior sinusitis demonstrate an increased risk for many rheumatic diseases, including antiphospholipid syndrome, Sjögren’s disease and seronegative rheumatoid arthritis, according to data published in RMD Open.

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The New England Journal of Medicine.

Patients who eventually developed giant cell arteritis demonstrated significantly higher levels of apolipoprotein A-I at baseline, according to population-based data published in Arthritis Research & Therapy.

The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

It’s not too often one sees Feb. 29 on the calendar, which makes it a perfect time for Rare Disease Day, dedicated to recognizing conditions that, in the words of the European Commission on Public Health, require “special combined efforts.”

SCOTTSDALE, Ariz. — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.

In this video, Audra Horomanski, MD, spoke with Healio about challenges in the vasculitis space.

In this video, Audra Horomanski, MD, discusses improving awareness of vasculitis management through provider education.